In 2006-2007, equine viral arteritis (EVA) was confirmed for the first time in Quarter Horses in multiple states in the USA. The entire genome of an equine arteritis virus (EAV) isolate from the index premises in New Mexico was 12 731 nt in length and possessed a previously unrecorded unique 15 nt insertion in the nsp2-coding region in ORF1a and a 12 nt insertion in ORF3. Sequence analysis of additional isolates made during this disease occurrence revealed that all isolates from New Mexico, Utah, Kansas, Oklahoma and Idaho had 98.6-100.0 % (nsp2) and 97.8-100 % (ORF3) nucleotide identity and contained the unique insertions in nsp2 and ORF3, indicating that the EVA outbreaks in these states probably originated from the same strain of EAV. 
INTRODUCTION
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA) in horses, a respiratory and reproductive disease that occurs in many equine populations throughout the world (Timoney & McCollum, 1993) . EAV is an enveloped virus with a single-stranded, positive-sense RNA genome of approximately 12.7 kb and belongs to the family Arteriviridae in the order Nidovirales (Cavanagh, 1997; Snijder & Meulenberg, 1998) . The genomic RNA comprises nine known open reading frames (ORFs) flanked by a 59 untranslated region (59UTR) and a 39UTR (Snijder & Meulenberg, 1998; Snijder et al., 1999) . ORF1a and -1b encode two replicase polyproteins (pp1a and pp1ab) that are processed post-translationally by three ORF1a-encoded proteinases (nsp1, -2 and -4) to yield at least 13 nonstructural proteins (nsp1-12, including nsp7a and 7b) (Snijder & Meulenberg, 1998; van Aken et al., 2006; Ziebuhr et al., 2000) . The other seven ORFs (2a, , respectively, encode the envelope proteins E, GP2, GP3, GP4, GP5 and M, and the nucleocapsid protein, N (Snijder & Spaan, 2006) . The EAV GP5 protein has been shown to carry the major neutralization determinants of the virus. Four major neutralization sites (A-D) in the N-terminal ectodomain of the GP5 protein have been identified, including aa 49 (A), 60-61 (B), 67-90 (C) and 98-106 (D) (Balasuriya et al., 1997 (Balasuriya et al., , 2004a Yamaguchi et al., 1997; Zhang et al., 2008b) .
The vast majority of EAV infections are inapparent or subclinical, but occasionally outbreaks of EVA occur that are frequently characterized by an influenza-like illness in adult horses, abortion in pregnant mares and interstitial pneumonia in very young foals Timoney & McCollum, 1993) . A variable percentage (from ,10 to 70 %) of stallions acutely infected with EAV can become persistently infected carriers, shedding the virus constantly in semen (Timoney & McCollum, 1993) . Carrier stallions transmit EAV venereally to susceptible mares following natural breeding or artificial insemination.
Infected mares can then disseminate the virus to susceptible cohorts with which they have close contact (Timoney & McCollum, 1988 Timoney et al., 1997) .
In 2006-2007, a multi-state occurrence of EVA was confirmed for the first time in Quarter Horses in the USA (Powell & Timoney, 2006; Timoney et al., 2006) sera from mares as well as serum and semen samples from the stallions on the index premises confirmed a diagnosis of EAV infection. Fresh cooled semen collected from one of the breeding stallions on the index premises in the late spring and early summer of 2006 together with donor/ recipient mares that had visited the index premises during the same time frame were traced to premises in 19 states (Fig. 1 ). Among these 19 states, EAV was isolated from horses on the premises of seven states (NM, UT, KS, OK, ID, CA and TX). In MT and AL, recent EAV infection was confirmed based on seroconversion or a significant (fourfold or higher) rise in neutralizing antibody titre to EAV between paired (acute and convalescent) sera, but no EAV isolates were obtained. In CO, animals had high antibody titres to EAV as well as epidemiological links to the index premises in NM, but no virus isolates were obtained. No virological or serological evidence of recent EAV infection was found in the nine remaining states (FL, IN, KY, LA, MN, MO, MS, SD and WY) that received shipped freshcooled semen and/or had mares visit the index premises in NM. This was the most extensive recorded occurrence of EVA resulting primarily from shipment of virus-infective semen and movement of donor or embryo recipient mares. In the course of this occurrence of EVA, EAV also spread to horses of another ten breeds in the USA (Table 1) .
Over the duration of the 2006-2007 EVA occurrence, EAV was isolated from 107 samples received from NM, UT, KS, OK, ID, CA and TX. These included 70 sequential isolates from the semen of 14 carrier stallions, 13 isolates from aborted fetuses, 18 from peripheral blood mononuclear cells (PBMCs) and six from sera. Four EAV isolates were obtained from the 2005 outbreak in NM; these comprised Fresh cooled semen from one of the infected stallions (stallion B) on the index premises in NM had been shipped to premises in a significant number of other states prior to 16 June 2006, when such shipments were suspended. The first EAV isolate (S3685) from the semen of this stallion (B) was subjected to full-length genome sequencing. The full-length sequence of S3685 was compared with that of the prototype virulent Bucyrus (VB) strain of EAV (North American phylogeny group, GenBank accession no. DQ846750; Balasuriya et al., 2007) and the CW96 strain of EAV (European phylogeny group, GenBank accession no. AY349167; Balasuriya et al., 2004b) . The complete genome of isolate S3685 was 12 731 nt in length and was 27 and 23 nt longer than the VB and CW96 strains of EAV, respectively. It had 1606 (87.3 % identity) and 1955 (84.6 % identity) nucleotide differences from the VB and CW96 strains of EAV, respectively, at the level of the entire genome. Among the replicase proteins, the greatest variation occurred in the nsp2 protein, followed by the nsp12 and nsp11 proteins (see Supplementary Table S1 , available in JGV Online). However, all predicted cleavage sites on the replicase polyproteins were conserved compared with the published sequence of the VB strain. Among the structural proteins, most variation occurred in the four envelope glycoproteins, GP2-5, with the greatest variation observed in the GP3 protein (Supplementary Table S1 ).
The genome of isolate S3685 contained a 15 nt insertion in the nsp2-coding region in ORF1a and a 12 nt insertion in ORF3 when compared with the VB and CW96 strains of EAV (Fig. 2) . The consecutive in-frame 15 nt insertion (59-GA-CGCCGTCCACAGT-39) was located between nt 1559 and 1560, resulting in the insertion of five amino acids (DAVHS) between aa 445 and 446 of the nsp2 protein (Fig. 2a) . The consecutive in-frame 12 nt insertion (59-AGTGCAT-TTGGA-39) was located between nt 10668 and 10669, resulting in the insertion of four amino acids (SAFG) between aa 121 and 122 of the GP3 protein (Fig. 2b ). Further analysis revealed that these insertions in nsp2 and ORF3 were absent from all previously sequenced EAV strains reported in the scientific literature or deposited in GenBank (data not shown), suggesting that EAV isolate S3685 from stallion B is a previously unrecorded strain of EAV.
To examine further the genetic characteristics of EAV isolates associated with the 2006-2007 EVA occurrence, nsp2 and ORF3 sequences were determined for 58 additional isolates, which comprised 21 isolates from the semen of 14 carrier stallions (stallions B-O) and all 37 EAV isolates from aborted fetuses, PBMCs and sera (Table 1 ). All isolates obtained from NM, UT, KS, OK and ID had 98.6-100 % (based on nsp2) and 97.8-100 % (based on ORF3) nucleotide identity with isolate S3685 and with each other; all contained the unique 15 nt insertion in the nsp2-coding region in ORF1a (Fig. 2a ) and the unique 12 nt insertion in ORF3 (Fig. 2b ). These findings were strongly indicative that the occurrence of EVA in these states originated from the same virus strain. In contrast, two EAV isolates obtained from TX (isolate S3955) and CA (isolate S4222) had significantly lower nucleotide identity with the outbreak isolates (S3955: 80.3-80.8 % nucleotide identity with the outbreak isolates based on nsp2 and 82.2-83.8 % based on ORF3; S4222: 83.7-84.2 % based on nsp2 and 82.2-83.8 % based on ORF3). Neither strain contained the characteristic 15 nt insertion in the Table S2 ). This suggested that the EAV genome is genetically relatively stable over the course of a short time frame. However, genomic variability tended to increase where horizontal and vertical transmission took place over a more extended time period.
Comparative amino acid sequence analysis of the 49 EAV isolates revealed that the potential N-glycosylation sites on the GP2 and GP4 proteins were conserved among all 49 isolates, whereas loss or acquisition of potential Nglycosylation sites occurred on GP3 and GP5 proteins (Fig. 4a ). In the case of the GP3 protein, potential Nglycosylation sites Asn-28, Asn-29, Asn-49, Asn-96 and Asn-106 were conserved in all 49 isolates. The amino acid substitution at residue 120 (SerAAsn) resulted in loss of the N-glycosylation site Asn-118 in two isolates (S3854 and S3943), but led to the acquisition of an additional putative N-glycosylation site, Asn-120, in these two isolates. In the case of the GP5 protein, the potential N-glycosylation sites Asn-56 and Asn-81 were conserved in all 49 isolates. A third potential N-glycosylation site at aa 73 (Asn-73) was observed for the first time on the GP5 protein of five EAV isolates obtained from clinical specimens from three different states (NM: M405 and M477 from aborted fetuses; UT: M517 from PBMCs and M547 from an aborted fetus; ID: M578 from an aborted fetus).
Genetic evolution of EAV during persistent infection in the stallion
The full-length genomic sequences of 18 EAV isolates sequentially collected from eight carrier stallions over an 8-26 month period (stallions A-H; three isolates from each of stallions A and C and two isolates from each of stallions B and D-H; Table 2 ) were determined to study the genetic evolution of EAV during persistent infection in the stallion. The complete genome of all 18 EAV isolates was 12 731 nt in length and each maintained the unique 15 nt insertion in nsp2 and 12 nt insertion in ORF3, although point mutations within the insertion region were observed for some isolates (Fig. 2) . Nucleotide and amino acid substitutions were observed in sequential isolates from all eight carrier stallions, but the evolution rate varied. As shown in 10681 G«A and 11372 TAA) nucleotide changes that occurred during persistent infection in three out of eight, four out of eight and five out of eight carrier stallions, respectively. The nucleotide mutations in ORF2a, -2b and -6 (encoding the E, GP2 and M proteins, respectively) were silent mutations and amino acid changes were only observed in the GP3 and GP5 proteins encoded by ORF3 and -5, respectively (Fig.  4c) .
To compare selective pressure exerted on individual EAV proteins, the ratios of the number of non-synonymous substitutions per non-synonymous site (dN) and synonymous substitutions per synonymous site (dS) were estimated. In this study, none of the dN : dS ratios estimated by pairwise comparison of all non-structural and structural coding regions of the EAV isolates from each of the eight carrier stallions was significantly greater than 1 (data not shown). Therefore, positive selection did not contribute significantly to nucleotide diversity of the EAV isolates during persistent infection in stallions. (14) S3583 and S4216 (26) S3685 and S3861 (8) S3699 and S3961 (11) S3699 and S4417 (24) S3712 and S4007 (11.5) S3711 and S4227 (18) S3854 and S4333 (14) S3886 and S4421 (16) S3943 and S4445 (15)
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DResults are shown as the number of nucleotide (amino acid) differences between each two indicated EAV isolates in the indicated genome regions. The interval between the collection dates of two sequential isolates is given in parentheses (months). dTotal number of nucleotide differences at the entire genome level. Because of the overlapping nature of each two adjacent ORFs, the total number of nucleotide differences is not the simple sum of the nucleotide differences of each ORF. Comparative amino acid sequence analysis of 18 EAV isolates from the eight carrier stallions revealed that the potential N-glycosylation sites on the GP2, GP4 and GP5 proteins were conserved during persistent infection in all eight carrier stallions. All EAV isolates from the eight carrier stallions had two potential N-glycosylation sites (Asn-56 and Asn-81) on the GP5 protein and the potential new N-glycosylation site, Asn-73, was not observed. However, loss or acquisition of potential N-glycosylation sites occurred in the GP3 protein during persistent infection in the stallion (Fig. 4b) . The potential Nglycosylation sites Asn-29, Asn-96 and Asn-106 were conserved during persistent infection in all eight carrier stallions. The substitution at aa 30 (ThrAIle) resulted in loss of the N-glycosylation site Asn-28 during persistent infection in three carrier stallions (B, D and G) . The substitution at aa 51 (ThrAIle) resulted in loss of the Nglycosylation site Asn-49 during persistent infection in carrier stallion E. The substitution at aa 120 (SerAAsn) resulted in loss of the N-glycosylation site Asn-118 in six isolates (S4417, S4007, S3854, S3943, S4445 and S3583), whereas an additional N-glycosylation site, Asn-120, was acquired by these six isolates.
Characterization of neutralization phenotypes of EAV isolates
A panel of 14 monoclonal antibodies (mAbs) and a panel of nine polyclonal equine antisera were used to characterize the neutralization phenotypes of 14 EAV isolates from this study as well as four previously described EAV strains (EAV ATCC, ARVAC, KY84 and CW96) for comparison. With the exception of the EAV M547 isolate, all of the isolates from this study were neutralized by mAbs 5G11, 6D10, 7E5, 9F2, 10F11, 10H4 and 6A2 (Table 3) . However, mAb 6A2 exhibited significant variability in its ability to neutralize different EAV isolates. The neutralizing mAbs 1H7, 1H9, 5E8, 7D4 and 10B4 did not neutralize any of the EAV isolates evaluated. With respect to the polyclonal equine sera, the M547 isolate was not neutralized to a high titre by EAV strain-specific polyclonal equine sera except for the anti-KY77 serum; all other EAV isolates were neutralized by the polyclonal equine sera, but the anti-ARVAC and anti-NVSL polyclonal equine sera generally neutralized these EAV isolates to a lower titre compared with the other antisera (Table 3 ). In summary, the neutralization data suggested that the M547 isolate had a distinct neutralization phenotype. Comparative amino acid sequence analysis of the critical neutralization regions of the GP5 protein of this isolate (Fig. 5) suggested that aa 62 (site B), 73 (site C), and 99 and 101 (site D) on the GP5 protein may contribute to its distinctive neutralization phenotype.
DISCUSSION
The seroprevalence of EAV infection can vary among horses of different breeds (Hullinger et al., 2001; McCollum & Bryans, 1973; McCue et al., 1991; Timoney & McCollum, 1993) . The 1998 National Animal Health Monitoring System's equine survey showed that only 0.6 % of the Quarter Horse population was seropositive to EAV (NAHMS, 2000) , indicating that the American Quarter Horse population was essentially totally naïve with respect to prior contact with EAV and, therefore, fully susceptible should future exposure to infection occur. In mid-2006, an EVA outbreak occurred on a large Quarter Horse breeding farm in NM, with EAV infection spreading rapidly in a presumed immunologically naïve horse population ) reported to date. The biological significance (e.g. the effects on virus growth, genome replication, virulence phenotype and abortion potential) of these insertions remains to be determined. Secondly, this study found some previously unrecognized potential N-glycosylation sites on the GP5 and GP3 proteins of EAV. The potential N-glycosylation site Asn-56 on GP5 has been conserved among all strains of EAV examined thus far. The presence of the potential N-glycosylation site Asn-81 on GP5 was variable; it has been observed in some field and laboratory strains of EAV (Balasuriya & MacLachlan, 2004) . A third potential N-glycosylation site, Asn-73, on GP5 was observed for the first time in this study. Its occurrence was variable and was identified only on some field isolates of EAV from this occurrence of EVA. The EAV isolates recovered from this disease occurrence had the potential N-glycosylation site Asn-118 or Asn-120, but J. Zhang and others not both, on the GP3 protein. Interestingly, it was the serine residue of the predicted 4 aa SAFG insertion (resulting from the 12 nt insertion in ORF3) that constituted the third residue of the N-glycosylation site Asn-120 (NXS, Fig. 4a, b) . Thirdly, this study identified several amino acid substitution sites in the EAV envelope proteins (GP3: aa 30, 120 and 121; GP5: aa 67 and 73) that were present consistently during persistent infection in the stallion. Interestingly, amino acid substitutions in GP3 (aa 30) and GP5 (aa 67 and 73) were also observed during persistent EAV infection in two long-term carrier stallions that had been characterized previously (Hedges et al., 1999) . Moreover, the M547 isolate from an aborted fetus in UT was found to have a distinct neutralization phenotype. This isolate was not neutralized by any of the mAbs that neutralized the other isolates. Similarly, this isolate was neutralized to a significantly lower titre by polyclonal equine sera compared with the other isolates. Sequence analysis suggested that amino acid residues in neutralization sites B, C and D may have contributed to the unique neutralization phenotype of this isolate. However, this needs to be confirmed by further reverse genetic studies.
A previous report suggested that the EAV genome remained genetically relatively stable during horizontal and vertical transmission in a disease outbreak on a Warmblood breeding farm in Pennsylvania . The 2006-2007 EVA occurrence spanned a period of more than 9-10 months of active circulation of EAV in horses of several breeds in multiple states. This event provided a unique opportunity to assess the genomic stability of EAV over an extended period of time, where the principal mode of virus transmission on affected premises was horizontal and vertical, and where several transmission cycles may have occurred. Data from this study suggested that the EAV genome remains genetically relatively stable over a short time period. However, genomic variability tended to increase if horizontal and vertical transmission took place over a more extended time period. Several studies have shown previously that genetic and phenotypic variation of EAV occurs during persistent infection in the stallion or in cell culture (Balasuriya et al., 2004b; Hedges et al., 1999; Zhang et al., 2008c) . However, such studies were based on a small number of carrier stallions and mostly on partial genomic sequences of the viruses involved. In this study, we determined the full-length genomic sequences of 18 EAV isolates collected sequentially from eight carrier stallions. It was evident that EAV evolved genetically during persistent infection in the stallion, but the evolution rate of the virus varied depending on the individual stallion and period of viral shedding. The longer the shedding period, the more mutations accumulated in the virus genome.
An extensive outbreak of EVA in Kentucky thoroughbreds in 1984 generated widespread interest, publicity and concern regarding this disease (Timoney, 1985 (Hamon, 2007; Pitel et al., 2007) have again increased awareness among horse owners and breeders of a disease that can have a significant financial impact on the equine industry. Over the years, importation of carrier stallions and virus-infective semen into the USA and certain European countries has unquestionably been responsible for the introduction of new strains of EAV and precipitation of EVA outbreaks (Balasuriya et al., 1998; Cullinane, 1993; Higgins, 1993; McCollum et al., 1999; Timoney et al., 1998) . Ironically, notwithstanding the economic significance of EAV infection to the US$102 billion year 21 horse industry in the USA (Owens, 2005) , to this date the USA stands alone as the only country with no import testing requirements or controls for EVA. Another feature of the 2006-2007 EVA occurrence is that movement of donor/recipient mares also contributed to virus transmission. The widespread practice of embryo transfer in the Quarter Horse breed and proliferation in the number of recipient mare farms in recent years were significant industry-driven factors not previously recognized as playing a role in the epidemiology of EVA . Hopefully, the 2006-2007 multistate EVA occurrence will convince the horse industry and the US animal regulatory authorities of the need to address prevention and control of EVA in a more progressive and determined manner.
METHODS
Cells. The rabbit kidney cell line RK-13 (ATCC CCL-37) was maintained in Eagle's minimum essential medium with 10 % ferritinsupplemented bovine calf serum, penicillin, streptomycin, amphotericin B and sodium bicarbonate. states that received shipments of fresh cooled semen from the index premises in NM and/or were associated with the movement of donor/ recipient mares submitted 2529 serum samples, 490 semen samples, 143 unclotted blood samples (PBMCs) and 47 aborted fetuses to the World Organization for Animal Health (OIE) EVA reference laboratory at the Gluck Equine Research Center (GERC) for serological and virological testing. One aborted fetus and three semen samples from the 2005 EVA outbreak in NM had been submitted earlier to the GERC.
Microneutralization assay. The neutralizing antibody titres of the test sera against EAV were determined in accordance with an OIEapproved test procedure (OIE, 2008) . The neutralization phenotypes of EAV isolates were determined by a microneutralization assay using 14 mAbs and nine polyclonal equine antisera as described previously (Balasuriya et al., 1995a (Balasuriya et al., , 1997 (Balasuriya et al., , 2004b .
Virus isolation. Isolation of EAV from semen, sera, PBMCs and fetal tissues was attempted in RK-13 cells according to an OIE-approved protocol (OIE, 2008) . The infective tissue culture fluids (TCFs) of the EAV isolates, each in its first passage level (P1) in cell culture, were stored at 280 uC. The identity of each EAV isolate was confirmed by real-time RT-PCR as described previously (Lu et al., 2008) .
Viral RNA extraction, RT-PCR amplification and sequencing.
Viral nucleic acid was extracted from the infective TCF (P1) containing each EAV isolate using a QIAamp Viral RNA Isolation Characterization of the 2006-2007 EVA outbreak isolates kit (Qiagen) according to the manufacturer's instructions. When determining the full-length genome sequence, the entire genome was amplified by RT-PCR in five overlapping fragments using Superscript III (Invitrogen) and the high-fidelity proofreading PfuTurbo DNA polymerase (Stratagene) according to previously described procedures (Zhang et al., 2008a; see Supplementary Table S3 , available in JGV Online). When determining the entire ORF2-7 sequences, ORF2-7 and the flanking portion of the EAV genome were RT-PCR-amplified using primers 9570P2 and 12687N (Supplementary Table S3 ). A similar approach was used to amplify the region (partial ORF1a) encoding the nsp2 protein using primers 833P and 3481N (Supplementary Table S3 ). The PCR products were gel-purified using a QIAquick Gel Extraction kit (Qiagen). Both sense and antisense strands were sequenced.
Sequence analysis. Sequence data were analysed using Aligner v3.0.1 (CodonCode), VectorNTI Advance 11 (Invitrogen) and BioEdit v7.0.0 (http://www.mbio.ncsu.edu/BioEdit/bioedit.html). Potential N-glycosylation sites were predicted using NetNGlyc (http://www.cbs.dtu.dk/services). Multiple sequence alignments were performed using CLUSTAL_X v1.83 (Thompson et al., 1997) . Estimates of dN and dS were calculated using the MEGA4.1 program (Tamura et al., 2007) . The dN : dS ratios were calculated for each nonstructural and structural protein gene using the method of Li et al. (1985) .
Phylogenetic analysis. EAV ORF5, especially the most variable region within ORF5 (518 nt in length from nt 11296 to 11813; numbered according to the sequence of the VB strain of EAV), has been used widely for phylogenetic studies (Balasuriya et al., 1995b; Hornyak et al., 2005; Larsen et al., 2001; Mittelholzer et al., 2006; Stadejek et al., 1999 Stadejek et al., , 2006 Zhang et al., 2007) . The sequence of this region of the 63 EAV isolates analysed in this study together with 287 additional sequences available from GenBank was used for phylogenetic analysis in the current study. The GenBank accession numbers and origins of these EAV isolates have either been reported previously by Zhang et al. (2007) or are provided in Table 1 . Unrooted neighbour-joining trees were constructed using MEGA4.1 (Tamura et al., 2007) .
